evertex fabrinology limited Logo

evertex fabrinology limited

1470.TW

(2.0)
Stock Price

20,30 TWD

4.94% ROA

6.11% ROE

31.64x PER

Market Cap.

1.899.739.050,00 TWD

6.17% DER

2.62% Yield

9.23% NPM

evertex fabrinology limited Stock Analysis

evertex fabrinology limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

evertex fabrinology limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (5%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

3 ROE

The stock's ROE falls within an average range (5.73%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (4.79%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's PBV ratio (1.68x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (240) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

evertex fabrinology limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

evertex fabrinology limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

evertex fabrinology limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

evertex fabrinology limited Revenue
Year Revenue Growth
2009 709.451.000
2010 811.037.000 12.53%
2011 789.031.000 -2.79%
2012 696.712.000 -13.25%
2013 669.101.000 -4.13%
2014 744.311.000 10.1%
2015 761.731.000 2.29%
2016 685.778.000 -11.08%
2017 701.061.000 2.18%
2018 754.462.000 7.08%
2019 818.166.000 7.79%
2020 630.757.000 -29.71%
2021 894.789.000 29.51%
2022 845.152.000 -5.87%
2023 582.208.000 -45.16%
2023 655.221.000 11.14%
2024 746.624.000 12.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

evertex fabrinology limited Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

evertex fabrinology limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 19.784.000
2010 21.302.000 7.13%
2011 23.684.000 10.06%
2012 21.930.000 -8%
2013 24.251.000 9.57%
2014 29.734.000 18.44%
2015 31.171.000 4.61%
2016 37.024.000 15.81%
2017 40.059.000 7.58%
2018 39.620.000 -1.11%
2019 43.435.000 8.78%
2020 33.264.000 -30.58%
2021 33.859.000 1.76%
2022 30.764.000 -10.06%
2023 29.264.000 -5.13%
2023 29.424.000 0.54%
2024 31.460.000 6.47%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

evertex fabrinology limited EBITDA
Year EBITDA Growth
2009 106.488.000
2010 116.602.000 8.67%
2011 97.958.000 -19.03%
2012 43.898.000 -123.15%
2013 80.827.000 45.69%
2014 121.338.000 33.39%
2015 116.023.000 -4.58%
2016 98.479.000 -17.81%
2017 86.554.000 -13.78%
2018 114.758.000 24.58%
2019 142.604.000 19.53%
2020 91.437.000 -55.96%
2021 135.155.000 32.35%
2022 103.249.000 -30.9%
2023 82.068.000 -25.81%
2023 108.284.000 24.21%
2024 124.700.000 13.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

evertex fabrinology limited Gross Profit
Year Gross Profit Growth
2009 118.202.000
2010 124.859.000 5.33%
2011 104.500.000 -19.48%
2012 67.646.000 -54.48%
2013 93.463.000 27.62%
2014 159.340.000 41.34%
2015 167.019.000 4.6%
2016 154.694.000 -7.97%
2017 150.354.000 -2.89%
2018 168.062.000 10.54%
2019 214.406.000 21.62%
2020 113.671.000 -88.62%
2021 191.121.000 40.52%
2022 174.318.000 -9.64%
2023 111.252.000 -56.69%
2023 129.818.000 14.3%
2024 185.560.000 30.04%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

evertex fabrinology limited Net Profit
Year Net Profit Growth
2009 53.361.000
2010 56.910.000 6.24%
2011 41.786.000 -36.19%
2012 14.777.000 -182.78%
2013 29.300.000 49.57%
2014 66.367.000 55.85%
2015 61.101.000 -8.62%
2016 46.956.000 -30.12%
2017 41.834.000 -12.24%
2018 48.867.000 14.39%
2019 75.861.000 35.58%
2020 35.414.000 -114.21%
2021 65.201.000 45.68%
2022 32.843.000 -98.52%
2023 21.952.000 -49.61%
2023 49.346.000 55.51%
2024 93.736.000 47.36%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

evertex fabrinology limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 1
2010 1 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 0 0%
2018 1 0%
2019 1 0%
2020 0 0%
2021 1 0%
2022 0 0%
2023 0 0%
2023 1 0%
2024 1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

evertex fabrinology limited Free Cashflow
Year Free Cashflow Growth
2009 75.091.000
2010 -17.411.000 531.28%
2011 24.129.000 172.16%
2012 15.515.000 -55.52%
2013 73.780.000 78.97%
2014 19.499.000 -278.38%
2015 53.072.000 63.26%
2016 81.618.000 34.98%
2017 -2.923.000 2892.27%
2018 36.748.000 107.95%
2019 59.183.000 37.91%
2020 17.373.000 -240.66%
2021 -1.318.000 1418.13%
2022 162.169.000 100.81%
2023 110.620.000 -46.6%
2023 17.574.000 -529.45%
2024 6.531.000 -169.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

evertex fabrinology limited Operating Cashflow
Year Operating Cashflow Growth
2009 109.628.000
2010 60.821.000 -80.25%
2011 75.641.000 19.59%
2012 39.196.000 -92.98%
2013 112.501.000 65.16%
2014 91.105.000 -23.48%
2015 86.975.000 -4.75%
2016 121.760.000 28.57%
2017 98.950.000 -23.05%
2018 106.069.000 6.71%
2019 95.193.000 -11.43%
2020 76.386.000 -24.62%
2021 43.834.000 -74.26%
2022 189.179.000 76.83%
2023 144.744.000 -30.7%
2023 23.305.000 -521.09%
2024 11.103.000 -109.9%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

evertex fabrinology limited Capital Expenditure
Year Capital Expenditure Growth
2009 34.537.000
2010 78.232.000 55.85%
2011 51.512.000 -51.87%
2012 23.681.000 -117.52%
2013 38.721.000 38.84%
2014 71.606.000 45.92%
2015 33.903.000 -111.21%
2016 40.142.000 15.54%
2017 101.873.000 60.6%
2018 69.321.000 -46.96%
2019 36.010.000 -92.5%
2020 59.013.000 38.98%
2021 45.152.000 -30.7%
2022 27.010.000 -67.17%
2023 34.124.000 20.85%
2023 5.731.000 -495.43%
2024 4.572.000 -25.35%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

evertex fabrinology limited Equity
Year Equity Growth
2009 830.385.000
2010 887.797.000 6.47%
2011 888.635.000 0.09%
2012 885.608.000 -0.34%
2013 907.290.000 2.39%
2014 950.496.000 4.55%
2015 959.602.000 0.95%
2016 948.012.000 -1.22%
2017 945.936.000 -0.22%
2018 937.043.000 -0.95%
2019 987.244.000 5.08%
2020 966.140.000 -2.18%
2021 1.005.950.000 3.96%
2022 972.984.000 -3.39%
2023 985.296.000 1.25%
2023 985.320.000 0%
2024 991.245.000 0.6%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

evertex fabrinology limited Assets
Year Assets Growth
2009 936.769.000
2010 996.588.000 6%
2011 1.004.290.000 0.77%
2012 993.143.000 -1.12%
2013 1.042.426.000 4.73%
2014 1.119.593.000 6.89%
2015 1.076.684.000 -3.99%
2016 1.076.698.000 0%
2017 1.120.348.000 3.9%
2018 1.134.243.000 1.23%
2019 1.180.196.000 3.89%
2020 1.173.413.000 -0.58%
2021 1.254.881.000 6.49%
2022 1.144.833.000 -9.61%
2023 1.132.464.000 -1.09%
2023 1.145.425.000 1.13%
2024 1.215.422.000 5.76%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

evertex fabrinology limited Liabilities
Year Liabilities Growth
2009 106.384.000
2010 108.791.000 2.21%
2011 115.655.000 5.93%
2012 107.535.000 -7.55%
2013 135.136.000 20.42%
2014 169.097.000 20.08%
2015 117.082.000 -44.43%
2016 128.686.000 9.02%
2017 174.412.000 26.22%
2018 197.200.000 11.56%
2019 192.952.000 -2.2%
2020 207.273.000 6.91%
2021 248.931.000 16.73%
2022 171.849.000 -44.85%
2023 147.168.000 -16.77%
2023 160.105.000 8.08%
2024 224.177.000 28.58%

evertex fabrinology limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.59
Net Income per Share
0.7
Price to Earning Ratio
31.64x
Price To Sales Ratio
2.92x
POCF Ratio
20.57
PFCF Ratio
28.29
Price to Book Ratio
1.92
EV to Sales
2.58
EV Over EBITDA
14.71
EV to Operating CashFlow
18.21
EV to FreeCashFlow
25.04
Earnings Yield
0.03
FreeCashFlow Yield
0.04
Market Cap
1,90 Bil.
Enterprise Value
1,68 Bil.
Graham Number
13.49
Graham NetNet
4.45

Income Statement Metrics

Net Income per Share
0.7
Income Quality
1.36
ROE
0.06
Return On Assets
0.05
Return On Capital Employed
0.05
Net Income per EBT
0.82
EBT Per Ebit
1.51
Ebit per Revenue
0.07
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.22
Operating Profit Margin
0.07
Pretax Profit Margin
0.11
Net Profit Margin
0.09

Dividends

Dividend Yield
0.03
Dividend Yield %
2.62
Payout Ratio
0.64
Dividend Per Share
0.58

Operating Metrics

Operating Cashflow per Share
1.08
Free CashFlow per Share
0.78
Capex to Operating CashFlow
0.27
Capex to Revenue
0.04
Capex to Depreciation
0.5
Return on Invested Capital
0.04
Return on Tangible Assets
0.05
Days Sales Outstanding
37.35
Days Payables Outstanding
17.82
Days of Inventory on Hand
112.32
Receivables Turnover
9.77
Payables Turnover
20.48
Inventory Turnover
3.25
Capex per Share
0.29

Balance Sheet

Cash per Share
5,57
Book Value per Share
11,56
Tangible Book Value per Share
11.56
Shareholders Equity per Share
11.56
Interest Debt per Share
0.72
Debt to Equity
0.06
Debt to Assets
0.05
Net Debt to EBITDA
-1.91
Current Ratio
3.32
Tangible Asset Value
0,99 Bil.
Net Current Asset Value
0,48 Bil.
Invested Capital
903574000
Working Capital
0,49 Bil.
Intangibles to Total Assets
0
Average Receivables
0,06 Bil.
Average Payables
0,02 Bil.
Average Inventory
138904000
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

evertex fabrinology limited Dividends
Year Dividends Growth
2011 0
2012 0 0%
2014 0 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 0 0%
2020 1 0%
2021 0 0%
2022 1 0%
2023 0 0%
2024 1 0%

evertex fabrinology limited Profile

About evertex fabrinology limited

evertex fabrinology limited manufactures and sells fabrics in Taiwan and internationally. The company offers Janerino, a hybrid merino wool fabric; BulkyStretch, a polyester knit fabric; Syncellux, a cellulose synthetic blend fabric; Tonissimo, a synthetic fleece fabric; functional fabrics; fabrics for trims, pocket and collar liners; and linings for casual and outdoor wears. The company was formerly known as Evertex Dyeing & Finishing. evertex fabrinology limited was founded in 1986 and is based in Taipei, Taiwan.

CEO
Poliang Yeh
Employee
264
Address
No. 64, Tacheng Street
Taipei, 103005

evertex fabrinology limited Executives & BODs

evertex fabrinology limited Executives & BODs
# Name Age
1 Poliang Yeh
President
70
2 Shian-Jung Hung
Vice President of Main Management Department , Chief Financial Officer & Corporate Governance Officer
70
3 Nan Hsu Chao
In-charge Accountant
70

evertex fabrinology limited Competitors